A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

NCT06948435 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medication orforglipron in adults who have both high blood pressure and excess weight or obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 487 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-04 · est. completion 2027-09

Where 99 sites · Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain, United States

What this study is testing ClinicalTrials.gov NCT06948435 ↗

Description as written by the study sponsor.

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

placebo administered.

Main thing measured	Change from Baseline in office Systolic Blood Pressure (SBP)
Sponsor	Eli Lilly and Company
Conditions studied	Hypertension, Overweight or Obesity
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06948435 ↗